A Phase I Study to Determine the Safety and Immunogenicity of Vaccination Regimens Employing the Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1
Latest Information Update: 18 Sep 2021
At a glance
- Drugs ChAdOx1-NP-M1 (Primary) ; VTP 100 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- 15 Dec 2015 Biomarkers information updated
- 21 Dec 2013 Accrual to date is 56% according to United Kingdom Clinical Research Network.
- 30 Nov 2013 Accrual to date is 54% according to United Kingdom Clinical Research Network.